SPY337.04+2.15 0.64%
DIA278.14+0.64 0.23%
IXIC11,326.51+159.00 1.42%

Credit Suisse Downgrades Satsuma Pharmaceuticals to Underperform, Lowers Price Target to $4

Credit Suisse downgrades Satsuma Pharmaceuticals (NASDAQ:STSA) from Outperform to Underperform and lowers the price target from $33 to $4.

· 09/11/2020 05:37
Credit Suisse downgrades Satsuma Pharmaceuticals (NASDAQ:STSA) from Outperform to Underperform and lowers the price target from $33 to $4.